A New Role for RNA
News Jan 04, 2016
Previously, genes that encode the recipe for making proteins have been implicated in maintaining the proper number of chromosomes in a cell. The NORAD gene, however, does not encode a protein. Instead, NORAD produces a long noncoding RNA, a type of molecule that was not previously known to be important in chromosome maintenance, the researchers report.
“In the absence of the NORAD RNA, the number of chromosomes in cells becomes highly abnormal,” explained Dr. Joshua Mendell, Professor of Molecular Biology at UT Southwestern and a Howard Hughes Medical Institute Investigator. “This is an entirely new function for a noncoding RNA and may have implications in cancer biology since genomic instability is a hallmark of tumor cells.”
Researchers began studying this particular molecule because the RNA kicks into action after DNA is damaged; they therefore termed it Noncoding RNA Activated by DNA Damage, or NORAD.
The scientists unexpectedly found that NORAD plays a critical role in keeping the genome stable, and conducted experiments showing that when NORAD is absent, cells frequently lose or gain whole chromosomes. Microscopic imaging revealed that cells lacking NORAD are unable to properly pass on chromosomes as they divide. NORAD controls chromosome segregation during cell division by regulating the activity of a family of proteins called PUMILIO proteins. In cells lacking NORAD, overactivity of PUMILIO leads to an unstable genome. Since most cancer cells also exhibit genomic instability, Dr. Mendell and his team are now exploring whether abnormal function of NORAD or PUMILIO proteins contribute to human tumors.
Dr. Mendell, a member of the Hamon Center for Regenerative Science and Medicine and the Harold C. Simmons Comprehensive Cancer Center, and a Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research, has been a leader in the study of other types of noncoding RNAs, including microRNAs, which are involved in regulating gene activity, and play important roles in development and disease. By investigating the roles of microRNAs and other noncoding RNAs, the Mendell lab is hoping to eventually develop new therapies that have the potential to treat cancer and other diseases.
Dr. Mendell, recipient of the 2016 Edith and Peter O’Donnell Award in Medicine from The Academy of Medicine, Engineering and Science of Texas (TAMEST), has previously shown how microRNAs play a key role in the ability of a well-known, cancer-promoting protein, MYC, to drive tumor formation. The Mendell lab has revealed involvement of microRNAs in several other critical cancer pathways and showed that these molecules are important for wound healing.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.